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PTATE-OF-THE-ART PAPERS
mplantable Cardioverter-
efibrillator Therapy in Clinical Practice
avid A. Cesario, MD, PHD,* G. William Dec, MD†
rvine, California; and Boston, Massachusetts
Pharmacologic treatment of heart failure has led to dramatic improvements in survival and
quality of life. Nonetheless, heart failure often progresses despite treatment with diuretics,
angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, aldosterone antagonists,
and digoxin. Further, despite a steady decline in the risk of death from pump failure, many
patients remain at high risk for sudden cardiac death. The annual incidence of sudden cardiac
death in the U.S. alone has been estimated at 184,000 to over 400,000 cases. During the past
decade, substantial advances have been made in the use of device-based therapy for this
population. The role of the implantable cardioverter-defibrillator (ICD) continues to evolve
in routine heart failure management. The current status of ICD therapy in the treatment of
heart failure patients based on randomized clinical trial results and published practice
guidelines is summarized in this review. (J Am Coll Cardiol 2006;47:1507–17) © 2006 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.077the American College of Cardiology Foundation
b
e
c
r
S
R
T
s
v
a
A
P
i
v
(
a
w
t
v
a
(
o
a
e
s
c
y
t
D
S
t
rdvances in the pharmacological therapy of chronic heart
ailure have led to significantly improved survival and
nhanced quality of life (1–3). Nonetheless, the risk of
udden cardiovascular death remains high in this growing
opulation. Current estimates of the annual incidence of
udden death in the U.S. range from 184,000 to over
00,000 cases (4–7). Randomized clinical trials have not
onvincingly shown that antiarrhythmic drug therapy can
ffectively reduce mortality in heart failure patients (8,9).
nfortunately, identifying high-risk populations has had
ittle effect on decreasing the cumulative incidence of
udden death in the population at large because the
ajority of sudden deaths occur among patients who do
ot have identifiable risk characteristics (10). The risk of
udden cardiac death (SCD) varies between 20% and 30%
mong patients with depressed left ventricular systolic
unction. Further, the risk of sudden death increases in a
early exponential manner as ejection fraction falls below
0% (10).
In addition to the severity of left ventricular dysfunction,
he degree of functional impairment by New York Heart
ssociation (NYHA) functional classification has also been
hown to be a powerful independent predictor of SCD
11,12). Although the absolute number of sudden deaths is
reatest for patients with NYHA functional class IV symp-
oms, sudden death accounts for only 35% of all-cause
ortality in this group of patients. Conversely, SCD ac-
ounts for 64% of deaths among patients with compensated
YHA functional class II heart failure symptoms
11,13,14). Thus, patients with mildly symptomatic (i.e.,
ell-compensated) heart failure should not be viewed as
From the *University of California-Irvine, Irvine, California; and the †Cardiology
ivision, Massachusetts General Hospital, Heart Failure and Transplantation Unit,w
oston, Massachusetts.
Manuscript received August 26, 2005, accepted September 29, 2005.eing at low risk for sudden death. A growing list of clinical,
lectrocardiographic, neurohumoral, and electrophysiologi-
al (EP) parameters may be useful for sudden cardiac death
isk stratification (10,15) (Table 1).
UBSETS OF PATIENTS AT THE HIGHEST
ISK OF SCD: PRIOR CARDIAC ARREST PATIENTS
he ICD remains the only evidence-based therapeutic
trategy for patients who have survived a life-threatening
entricular arrhythmic event (i.e., out-of-hospital cardiac
rrest). Table 2 lists the American College of Cardiology/
merican Heart Association/North American Society for
acing and Electrophysiology 2002 guidelines for ICD
mplantation. Three prospective, controlled secondary pre-
ention trials have specifically examined this population
Table 3) (16–18). The Antiarrhythmics Versus Implant-
ble Defibrillators (AVID) trial enrolled 1,016 patients who
ere resuscitated from either ventricular fibrillation, sus-
ained ventricular tachycardia with syncope, or sustained
entricular tachycardia with an ejection fraction of 40%,
nd symptoms suggesting severe hemodynamic compromise
19). Eligible patients were randomized to receive an ICD
r treatment with a class III antiarrhythmic drug, primarily
miodarone, at empirically determined doses. The primary
nd point of this trial was all-cause mortality. Overall
urvival was greater for patients receiving ICD treatment
ompared with antiarrhythmic drug therapy at 1, 2, and 3
ears (p  0.02) (19). Similar results have been reported in
wo small, randomized trials—the Canadian Implantable
efibrillator Study (CIDS) (17) and the Cardiac Arrest
tudy Hamburg (CASH) (18). Pooled data from these
hree secondary prevention trials indicate that ICD therapy
educes mortality risk by 35%. Absolute two-year mortality
as reduced from 23% in the medically treated cohort to
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Implantable Cardioverter-Defibrillators April 18, 2006:1507–175.5% in the ICD cohort. Finally, a recent large retrospec-
ive observational study of over 6,900 patients admitted to
eteran’s Administration hospitals evaluated the efficacy of
CD therapy (n 1,442) versus medical management alone
mong patients with new-onset ventricular arrhythmias
ventricular tachycardia, fibrillation, or cardiac arrest) and
nown ischemic heart disease (20). Multivariate regression
nalysis that adjusted for demographics, illness acuity, and
edical comorbidities showed ICD treatment to signifi-
antly lower all-cause mortality (odds ratio, 0.52; 95%
onfidence interval, 0.45 to 0.60) at three-year follow-up.
owever, no significant differences were noted between
roups in cardiovascular mortality rates. The greatest benefit
f ICD therapy in all studies was observed among patients
ith advanced left ventricular systolic dysfunction (16,19)
Table 3). Little advantage over drug therapy has been
Abbreviations and Acronyms
ARVD  arrhythmogenic right ventricular dysplasia
ECG  electrocardiogram
EP  electrophysiological
HCM  hypertrophic cardiomyopathy
ICD  implantable cardioverter-defibrillator
LQTS  long QT syndrome
NYHA  New York Heart Association
SCD  sudden cardiac death
able 1. Indicators of an Increased Risk of Sudden Death From
Risk Factors
onventional coronary risk factors
High cholesterol
High blood pressure
Smoking
Diabetes
linical markers
NYHA functional class
Ejection fraction
aseline ventricular arrhythmia
Premature ventricular depolarizations
Non-sustained ventricular tachycardia
Sustained ventricular tachycardia
lectrocardiographic variables
Standard ECG
Left ventricular hypertrophy
Widened QRS complex
QT dispersion
Specific abnormalities (e.g., prolonged QT interval, right bundle bran
block plus ST-segment elevation in V1 [Brugada syndrome], ST-
T-wave abnormalities in V1 and V2 [right ventricular dysplasia], d
waves [Wolf-Parkinson-White syndrome])
igh-resolution ECG
Late potentials on signal-averaged ECG
T-wave alternans
arkers of autonomic nervous function
Heart rate variability
Baroreflex sensitivity
lectrophysiologic testing
Inducibility of sustained tachyarrhythmia by programmed electrical stimeprinted, with permission, from Huikuri et al. (10).
ECG  electrocardiogram; NYHA  New York Heart Association.bserved in patients with an ejection fraction that exceeds
5% (21). Electrophysiological studies, performed after
esuscitation, are insensitive predictors of risk for recurrent
ife-threatening arrhythmias during long-term follow-up.
NHERITED ION CHANNELOPATHIES
LONG QT AND BRUGADA SYNDROMES)
ong QT syndrome (LQTS) is a group of inherited
isorders caused by mutations of the genes encoding the
tructure of cardiac ion channels. To date, mutations affect-
ng seven genes on six different chromosomes have been
dentified in this disorder. Affected patients classically have
prolonged corrected QT interval on surface electrocardio-
ram (ECG) associated with a propensity to syncope,
borted cardiac arrest, and sudden cardiac death (22–25).
ecent data indicate that beta-blocker therapy is effective in
bout 70% of LQTS patients; however, 30% of these
atients are still at increased risk for adverse cardiac events
espite optimal treatment including aggressive beta-
lockade (26). A recent study evaluated ICD implantation
n high-risk LQTS patients, defined as those with a history
f prior cardiac event (either cardiac arrest, recurrent syn-
ope, or LQTS-related sudden cardiac death in a close
amily member). In this study, there was a 1.3% death rate
mong patients receiving ICDs during an average follow-up
f three years, whereas non-ICD patients experienced a
ricular Arrhythmia
Predictive Power
Low power to discriminate the individual person at risk for
sudden death
High power to predict death from cardiac causes; relatively low
specificity to predict death from arrhythmia
Low overall power if not combined with other variables;
higher predictive power with low ejection fraction
Low power to predict death from arrhythmia
Higher degree of accuracy in identifying specific electrical
abnormalities
High negative predictive value but low positive predictive value
Primary predictive value unknown
Exact predictive value unknown
n High degree of accuracy in specific high-risk subgroupsVent
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April 18, 2006:1507–17 Implantable Cardioverter-Defibrillators6% death rate during a mean follow-up time of eight years
27). The results of this study strongly suggest that ICDs
hould be implanted in LQTS patients with prior cardiac
rrest or recurrent syncope despite beta-blocker therapy.
ecause of the small number of patients with LQTS, our
nderstanding of which patients require protection via ICD
mplantation remains incomplete; thus, standard guidelines
or ICD implantation in LQTS patients are currently
navailable. Additional subgroups of LQTS patients at high
isk of SCD who may benefit from ICD therapy include
atients with known SCN5A mutations (these patients tend
able 2. ACC/AHA/NASPE 2002 Guidelines for Implantable C
lass I Indications
Cardiac arrest due to VT or VF, not due to a transient reversible cause
Spontaneous sustained VT in association with structural heart disease.
Syncope of undetermined origin with clinically relevant, hemodynamica
when drug therapy is ineffective, not tolerated, or not preferred.
Non-sustained VT in patients with coronary artery disease, prior MI, a
suppressed by class I antiarrhythmic drugs.
lass IIa Indications
Patients with left ventricular ejection fraction 30%, at least one mont
lass IIb Indications
Cardiac arrest presumed to be due to VF when EPS is precluded by ot
Severe symptoms (e.g., syncope) attributed to VT in patients awaiting
Familial or inherited conditions with a high risk of life-threatening VT
Non-sustained VT with CAD, prior MI, LV dysfunction, and inducib
Recurrent syncope of undetermined etiology in the presence of LV dys
other cause of syncope has been excluded.
Syncope in patients with advanced structural heart disease in which tho
has not shown a cause.
lass III Indications
Incessant VT or VF.
Significant psychiatric illnesses that may be aggravated by device implan
Patients with CAD, LV dysfunction, and prolonged QRS duration in
sustained or non-sustained VT who are undergoing CABG.
NYHA functional class IV drug-refractory heart failure patients who ar
eprinted, with permission, from Gregoratos et al. (44).
CABG  coronary artery bypass grafting; CAD  coronary artery disease; EPS
yndrome; LV  left ventricular; MI  myocardial infarction; NYHA  New York
able 3. Randomized Trials of Implantable Cardioverter-Defibril
Trial
No. of
Patients
CHF*
(% of pts) LVEF (%)
econdary prevention trials
AVID 1,016 43 35
CIDS 659 32 34
CASH 288 74 45
rimary prevention trials
MADIT I 196 60 26
MADIT II 1,232 60 23
CABG-Patch 900 73 27
CAT 104 100 24
AMIOVERT 103 85 22
DEFINITE 450 88 21
SCD-HeFT 2,521 100 25
CHF  NYHA functional class II or III symptoms.
AMIOVERTAmiodarone Versus Implantable Cardioverter Defibrillator Randomize
rtery Bypass Graft Patch; CASHCardiac Arrest Study Hamburg; CATCardiomy
mplantation in Non-Ischemic cardiomyopathy Treatment Evaluation; ICD  implantable ca
ulticenter Automatic Defibrillator Implantation Trial; SCD-HeFT  Sudden Cardiac Do have more lethal events and less efficacy from beta-
locker therapy) (28), those with a strong family history of
udden cardiac death, and those intolerant of beta-blockers.
Brugada syndrome is an inherited disorder associated
ith increased cardiac arrhythmias caused by loss of func-
ion mutations in the SCN5A sodium channel gene. This
isorder is characterized by the typical surface ECG pattern
f incomplete right bundle branch block and ST-segment
levation in leads V1 to V3, and an increased risk of sudden
ardiac death as the result of ventricular fibrillation (29).
atients with Brugada syndrome have been reported to have
overter-Defibrillators
Level of Evidence
A
B
nificant VT or VF induced at EPS B
ducible VT at EPS that is not A
t-MI, and three months post-CABG. B
edical conditions. C
c transplantation. C
as LQTS or HCM. B
tained VT or VF at EPS. B
on and inducible VT at EPS when C
invasive and non-invasive investigation C
C
n or may preclude systematic follow-up. C
sence of spontaneous or inducible B
candidates for cardiac transplantation. C
ctrophysiologic testing; HCM  hypertrophic cardiomyopathy; LQTS  long QT
t Association; VF  ventricular fibrillation; VT  ventricular tachycardia.
Therapy
Control Treatment
% Mortality
Control Patients ICD p Value
miodarone or sotalol 24 16 0.02
miodarone 30 25 0.14
miodarone or metoprolol 44 36 0.08
onventional 39 16 0.009
onventional 20 14 0.007
o ICD 21 22 0.64
o ICD 31 26 0.55
miodarone 13 12 0.80
o ICD 14 8 0.06
o ICD 29 22 0.007
l; AVIDAntiarrhythmics versus Implantable Defibrillators; CABGPatchCoronary
Trial; CIDSCanadian Implantable Defibrillator Study; DEFINITEDEFibrillatorardi
.
lly sig
nd in
h pos
her m
cardia
such
le sus
functi
rough
tatio
the ab
e notlator
A
A
A
C
C
N
N
A
N
N
dTria
opathyrdioverter-defibrillator; LVEF  mean left ventricular ejection fraction; MADIT 
eath-Heart Failure Trial.
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Implantable Cardioverter-Defibrillators April 18, 2006:1507–17cardiac arrest risk as high as 30% during a three-year
ollow-up period (30). Currently, there are no standard
ractice guidelines describing ICD implantation recom-
endations for patients with Brugada syndrome. Patients at
igh risk for sudden cardiac death have been identified by
he presence of ST-segment elevation on surface ECG leads
1 to V3 at baseline and a history of syncope (31). These
atients should be seriously considered for ICD implantation.
ow-risk patients have been identified as silent mutation
arriers or patients who have diagnostic ECG characteristics
nly after a provocative challenge (31). The cardiac arrest
ate in these patients has been reported as only 5% during
our decades of follow-up. Finally, Priori et al. have defined
group of Brugada patients at intermediate risk for cardiac
rrest. These patients have spontaneous ST-segment eleva-
ion 2 mm without a previous history of syncope; 14% of
hem had a cardiac arrest during follow-up (31). Treatment
ecommendations for intermediate-risk Brugada patients
ust be evaluated on an individual case basis with family
istory and patient preference playing a key role in the
ecision-making process.
YPERTROPHIC CARDIOMYOPATHY
ypertrophic cardiomyopathy (HCM) is the most common
enetic cardiac disorder with an incidence of about 1 in 500
ersons in the general population (32–34). Hypertrophic
ardiomyopathy is caused by a variety of gene mutations in
he proteins encoding components of the cardiac sarcomere
35,36). This disorder is characterized by widely heteroge-
eous clinical, morphologic, and genetic expressions (37).
udden death occurs in affected patients as a consequence of
n electrically unstable myocardial substrate with re-entrant
entricular tachyarrhythmias brought on by the presence of
yocardial architectural disarray, interstitial scarring, mi-
rovascular insufficiency, and myocardial ischemia. Hyper-
rophic cardiomyopathy is the most common cause of
udden cardiac death in young athletes and accounts for
0% to 50% of the sudden deaths in this population (38).
rug therapy, including beta-blockers and amiodarone,
lcohol septal ablation, or septal myomectomy have not
able 4. Predictors of High Risk for Sudden Cardiac Death
n Hypertrophic Cardiomyopathy
rior cardiac arrest (VF)
pontaneous sustained ventricular tachycardia (VT)
amilial history of sudden death (particularly first-degree or multiple
relatives)
yncope (particularly recurrent, exertional, or occurring in the young)
on-sustained VT on ambulatory monitoring
bnormal blood pressure response to aerobic exercise testing (decrease
or failure to augment by 20 mm Hg in patients 50 years old)
xtreme left ventricular hypertrophy (30 mm by echocardiography)
pecific lethal molecular mutations of myosin heavy chain (Arg403Gln;
Arg19Trp), troponin T (intron 15 G1 to A1 Ile79Asn; Arg92Gln)
and -tropomyosin
bbreviations as in Table 3.een shown to be effective in lowering the risk of sudden
c
teath in HCM patients. Although there is a predilection for
udden death in younger patients (30 years of age), older
ge alone does not confer immunity from this complication.
Risk stratification should be undertaken for all patients
ith known HCM, especially those 50 years of age.
valuation should comprise a detailed personal and family
istory, physical examination including provocative maneu-
ers, 12-lead ECG, two-dimensional echocardiography
ith assessment of resting and provoked ventricular outflow
ract gradients, 24-h ambulatory ECG monitoring, and
xercise testing. The strongest risk factors for sudden death
re summarized in Table 4. Massive left ventricular hyper-
rophy (interventricular septal wall thickness 30 mm) is a
owerful independent marker for sudden death, even in the
bsence of demonstrable ventricular arrhythmias (39). Al-
hough approximately 50% of clinically identified hypertro-
hic cardiomyopathy patients have one or more markers of
ncreased SCD risk, almost 50% of those who ultimately
xperience SCD have no risk factors (40).
An ongoing challenge is the more precise identification of
atients who should be targeted for primary prevention via
CD implantation. Table 5 outlines one proposed scoring
ystem to identify high-risk HCM patients. The develop-
ent of genetic markers of sudden death risk holds great
romise as a potential future risk stratifier for this popula-
ion. However, it remains unclear whether identifying
pecific disease-causing mutations will prove useful in pre-
icting prognosis and designing effective treatment strate-
ies for individual HCM patients (41,42). A multi-center
etrospective analysis of high-risk HCM patients confirmed
he efficacy of ICD therapy (43). The ICD reliably aborted
otentially lethal ventricular arrhythmias in almost 25% of
atients over a three-year period. Appropriate device inter-
entions occurred at a rate of 11% per year for secondary
revention, and about 5% per year for primary prevention
43). The ratio of devices implanted to lives saved in this
tudy was calculated at 4:1. At present, ICD placement
emains a class IIb indication for primary prevention in this
able 5. Hypertrophic Cardiomyopathy: Scoring System
or Identification of High-Risk Patients
Risk Factor RR (95% CI)
xercise BP 2.4 (1.0–5.5)
yncope 2.0 (0.8–4.9)
on-sustained VT 1.8 (0.7–4.7)
amily history of sudden death 1.9 (0.8–4.1)
V wall thickness 30 mm 4.1 (1.7–9.5)
Risk Score
(No. of Risk Factors)
6-Year Sudden
Cardiac Death Risk
0 5% (1%–9%)
1 7% (1%–13%)
2 18% (4%–33%)
3 35% (25%–100%)
eprinted, with permission, from Elliot et al. (40).
BP  blood pressure decrease or failure to augment during exercise testing; CI onfidence interval; LV  left ventricular; RR  relative risk; VT  ventricular
achycardia.
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uidelines (44).
RRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA
rrhythmogenic right ventricular dysplasia (ARVD) is
haracterized by varying degrees of patchy replacement of
ight ventricular myocardium with fatty or fibrous-fatty
issue (45). It is frequently transmitted in an autosomal-
ominant manner, with disease-causing mutations identi-
ed in genes encoding the cell adhesion proteins, plakoglo-
in and desmoplakin (46,47). A family history is present in
0% to 50% of affected patients (47–49), and male patients
eem to be disproportionately affected. The ARVD patients
ost frequently suffer from palpitations or syncope associ-
ted with a left bundle branch block pattern of ventricular
achycardia that originates in the right ventricle.
An ARVD has been reported to be the underlying cause
or 3% to 10% of unexplained sudden cardiac deaths in
atients 65 years old (45,50); ECG abnormalities are
etected in up to 90% of patients diagnosed with ARVD
51). T-wave inversion in leads V1 to V3 is the most
ommon finding; however, these repolarization abnormali-
ies are not pathognomonic for ARVD and may be seen in
ormal children or may be secondary to right bundle branch
lock. Additional ECG abnormalities that may be seen in
RVD and result from delayed right ventricular activation
nclude right bundle branch block and epsilon waves (small
mplitude potentials occurring immediately after the QRS
omplex at the beginning of the ST-segment) (45,52).
reviously, the diagnosis of ARVD was made by endomyo-
ardial biopsy, showing typical fibro-fatty replacement of
he right ventricular muscle (52). However, endomyocardial
iopsy has a low sensitivity because samples are usually
aken from the ventricular septum to avoid cardiac perfora-
ion, and this region is uncommonly involved in ARVD.
dditionally, it can be difficult to differentiate ARVD from
ther causes of right ventricular myocardial fatty infiltration.
hus, endomyocardial biopsy should be reserved for selected
atients in whom the final diagnosis depends on the
istological exclusion of other cardiomyopathic conditions.
Evaluation of the heart by one of the common imaging
odalities is an integral part of the diagnostic workup. The
iagnosis of ARVD can be supported by cardiac magnetic
esonance imaging, and the risk of sudden cardiac death
eems to be related to the extent of fatty replacement of the
ight and/or left ventricles, as well as the degree of systolic
ysfunction. However, the fibro-fatty replacement in
RVD can sometimes be microscopic, rendering a defini-
ive diagnosis even by magnetic resonance imaging difficult
n some borderline cases (53).
Identification of ARVD patients at high risk for sudden
ardiac death is critical in deciding which patients should
eceive ICD therapy. Several retrospective studies have
hown potential predictors of adverse outcomes in ARVD
atients (Table 6) (54). In a recent multicenter trial, ICD rherapy resulted in a significant improvement in survival
ates among selected ARVD patients (55). Patients with a
istory of syncope or frequent runs of ventricular tachycar-
ia should generally have an ICD implanted. Predictors of
ppropriate ICD firing have been reported to include
nducible ventricular tachycardia during EP testing, detec-
ion of spontaneous ventricular tachycardia, male gender,
nd marked right ventricular dilatation (56). The EP
tudies have uncertain predictive value among asymptom-
tic patients despite documented disease. The current
CC/AHA/NASPE practice guidelines do not yet offer
pecific recommendations on the management of asymp-
omatic individuals once the diagnosis of ARVD has
een established.
RIMARY PREVENTION OF SUDDEN
EATH IN ISCHEMIC CARDIOMYOPATHY
everal randomized clinical trials have evaluated ICD treat-
ent for primary prevention of sudden cardiac death among
atients with impaired left ventricular systolic function due
o underlying ischemic heart disease. The first Multicenter
utomatic Defibrillator Implantation Trial (MADIT I)
andomized 196 patients with coronary artery disease,
pontaneous non-sustained ventricular tachycardia during
P testing, a left ventricular ejection fraction 35%, and
nducible ventricular tachycardia that was not suppressed
uring intravenous procainamide administration to an im-
lantable defibrillator or conventional medical therapy (57).
he ICD implantation resulted in a significant reduction in
verall mortality: there were 15 deaths in the defibrillator
roup compared with 39 deaths in the EP-guided conven-
ional treatment group (risk reduction, 54%) (57).
The Coronary Artery Bypass Graft Trial (CABG Patch)
andomized 900 patients already scheduled for elective
oronary revascularization surgery who also had a left
entricular ejection fraction below 36% and an abnormal
ignal-averaged ECG to undergo ICD implantation versus
o ICD (control group) at the time of their coronary artery
ypass graft surgery (58). In this trial, there were 101 deaths
mong the 454 patients who received defibrillators (22%)
ersus 95 deaths among the 446 control patients (21%). The
able 6. Proposed Risk Factors for Poor Prognosis in
rrhythmogenic Right Ventricular Dysplasia
revious cardiac arrest
yncope or sustained ventricular tachycardia with impairment of
consciousness
ncreased QT dispersion (a difference of 40 ms between the
maximum and minimum QRS values occurring in any of the
12 electrocardiographic leads)
arly onset of symptoms
evere right ventricular dilatation
ight heart failure
eft ventricular involvement (regional wall motion abnormalities or
dilatation and impairment of left ventricular systolic function)
eprinted, with permission, from Sen-Chowdhry S et al. (54).elative risk ratio for death in ICD patients was 1.07 (95%
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Implantable Cardioverter-Defibrillators April 18, 2006:1507–17onfidence interval, 0.81 to 1.42; p  not significant). It
hould be noted that the majority of deaths in the ICD
roup occurred in the peri-operative period; further, 10% of
he control group eventually crossed over to receive ICD
herapy during the trial (58).
The Multicenter Unsustained Tachycardia Trial (MUSTT)
nrolled a patient population similar to that of the MADIT
trial and evaluated the efficacy of EP-guided antiarrhyth-
ic therapy. Patients with inducible ventricular tachycar-
ia on EP testing (n  704) were assigned to receive
ither conventional medical therapy or antiarrhythmic
herapy as guided by serial EP testing (8). Individuals
ould receive an ICD without randomization (n  161)
f one or more drug trials showed inadequate arrhythmia
uppression. At 5-year follow-up, all-cause mortality was
4% in the ICD group, 55% for patients who received
P-guided antiarrhythmic therapy and 48% in patients
ho did not receive any antiarrhythmic treatment (p 
.001) (8).
The second MADIT II trial enrolled 1,232 patients with
schemic cardiomyopathy and ejection fractions 30%. No
ocumentation of spontaneous or inducible arrhythmias was
equired for enrollment (58). Antiarrhythmic therapy was
rescribed in 20% of both groups. During an average
ollow-up of 20 months, all-cause mortality was 20% in the
ontrol group versus 14.2% in the defibrillator group (59).
he hazard ratio for death in the ICD group was 0.69 (95%
onfidence interval, 0.51 to 0.93; p  0.016). A recent
eta-analysis of all major primary prevention sudden car-
iac death trials showed a significant benefit in favor of ICD
lacement with a risk reduction for all-cause mortality of
4% (p  0.03) (60). Current practice guidelines support
CD implantation as a primary prevention strategy in
atients with a prior myocardial infarction, left ventric-
lar ejection fraction 30%, and QRS duration 120 ms
Table 2) (44).
It should be noted that the recently published Defibril-
ator in Acute Myocardial Infarction Trial (DINAMIT)
andomized 674 patients who had recently suffered a myo-
ardial infarction (6 to 40 days after myocardial infarction),
ad a left ventricular ejection fraction 35%, and had
mpaired cardiac autonomic function (decreased heart rate
ariability or elevated average heart rate as determined by
4-h ambulatory monitoring) to receive either ICD implan-
ation or no ICD therapy (61). A percutaneous coronary
ntervention on the infarct-related artery was performed in
nly 36% of study patients. During a follow-up period of
0  13 months, there was no significant difference in
verall mortality between the two treatment groups (61).
owever, annual mortality rates were low in both groups,
.5% for ICD-treated patients and 6.9% for control pa-
ients. These results suggest that the prophylactic use of
CD placement within the first month after acute myocar-
ial infarction remains of unproven benefit. IRIMARY PREVENTION OF SUDDEN
EATH IN NON-ISCHEMIC CARDIOMYOPATHY
he role of defibrillator therapy for the primary prevention
f sudden death in patients with non-ischemic cardiomy-
pathy has remained controversial; however, several recent
rials suggest a beneficial role for ICDs in this population.
he Cardiomyopathy Trial (CAT) enrolled 104 patients
ith recent onset of non-ischemic dilated cardiomyopathy
9 months) and an ejection fraction 30% (62). Patients
ere assigned to either ICD implantation or conventional
herapy. The primary end point was all-cause mortality at
ne year of follow-up. The trial was terminated after
nrollment of only 104 patients because the all-cause
ortality at one year did not reach the expected 30% in the
ontrol group. No significant difference in survival was
oted among patients undergoing ICD implantation com-
ared with control patients in this underpowered trial (62).
imilarly, the recently published Amiodarone Versus Im-
lantable Cardioverter Defibrillator Trial (AMIOVIRT)
howed no improvement in survival or arrhythmia-free
urvival with ICD therapy as compared with amiodarone
reatment in 103 patients with non-ischemic dilated cardio-
yopathy, left ventricular ejection fractions 35%, and
symptomatic non-sustained ventricular tachycardia (63). It
hould be noted that Fonarow et al. (64) in a non-
ontrolled, retrospective, observational study have reported
hat patients with heart failure due to non-ischemic cardio-
yopathy and a prior history of syncope have a significant
eduction in sudden death risk and improvement in overall
urvival after ICD implantation when compared with his-
orical control patients. The prognostic importance of
yncope was confirmed in a small study by Knight et al.
65) that reported a high incidence of appropriate ICD
rings among patients with non-ischemic cardiomyopa-
hy and prior unexplained syncope, even when non-
nducibility was present during initial EP testing. Addi-
ionally, Grimm et al. found that ICDs implanted for
rimary prevention in patients with idiopathic dilated
ardiomyopathy and reduced left ventricular ejection
ractions (30%) had an appropriate ICD firing rate
imilar to that of patients with a history of syncope or
ustained ventricular tachycardia/ventricular fibrillation
66).
The Defibrillators in Non-Ischemic Cardiomyopathy
reatment Evaluation (DEFINITE) trial randomized 458
atients with non-ischemic dilated cardiomyopathy, left
entricular ejection fractions 36%, and 10 premature
entricular complexes per hour or non-sustained ventricular
achycardia on 24-h ambulatory monitoring to receive
tandard medical therapy alone, or in combination with a
ingle-chamber ICD (67). All patients had NYHA func-
ional class II or higher heart failure symptoms within six
onths of randomization. Patients who had NYHA func-
ional class IV heart failure, who were not candidates for
CD implantation, had undergone EP testing within the
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April 18, 2006:1507–17 Implantable Cardioverter-Defibrillatorsrevious three months, or had a permanent pacemaker were
xcluded. Over 95% of enrolled patients were receiving
ither an angiotensin-converting enzyme inhibitor or angio-
ensin receptor blocker. Additionally, 85% of enrolled pa-
ients received beta-blockers. The primary end point of the
rial was all-cause mortality; patients were followed up for a
ean of 29  14.4 months. There was a trend toward
mproved overall 24-month survival in patients undergoing
CD implantation (hazard ratio, 0.65; 95% confidence
nterval, 0.40 to 1.06); however, this failed to reach statis-
ical significance (p  0.08) (65). This trial did show a
ignificant and striking reduction in a key secondary end
oint, the risk of sudden death from arrhythmia (hazard
atio, 0.20; 95% confidence interval, 0.06 to 0.71) in ICD
atients.
The recently completed Sudden Cardiac Death in Heart
ailure Trial (SCD-HeFT) was a three-armed study that
andomized 2,521 patients with left ventricular ejection
ractions 35%, ischemic (52%) or non-ischemic (48%)
ardiomyopathy, and NYHA functional class II (70%) or III
30%) heart failure symptoms to conventional pharmaco-
ogical therapy alone, or in combination with either amio-
arone or a single-lead ICD (9). Median follow-up aver-
ged 45.5 months. The SCD-HeFT trial showed a
ignificant reduction in total mortality in the ICD cohort
hazard ratio, 0.77; 97.5% confidence interval, 0.62 to 0.96).
miodarone therapy failed to improve survival (hazard
atio, 1.06; 97.5% confidence interval, 0.86 to 1.30). The
urvival benefit was similar in magnitude between ischemic
atients (hazard ratio, 0.79; p  0.05) and non-ischemic
ardiomyopathy patients (hazard ratio, 0.73; p  0.06), but
emained of marginal statistical significance. Curiously, the
ortality benefit was confined to patients with mild
NYHA functional class II) symptoms in the SCD-HeFT
nd moderate symptoms (NYHA functional class III) in the
EFINITE trial (9,67). At present, prophylactic ICD
herapy is not recommended by AHA/ACC/NASPE
uidelines for primary prevention in patients with moderate
eart failure symptoms due to non-ischemic cardiomyopa-
hy (Table 2) (44); however, the recent DEFINITE and
CD-HeFT findings will almost certainly result in a change
n these recommendations favoring more widespread use of
CDs in the non-ischemic heart failure population when left
entricular ejection fraction is 35%, as reflected in the
ecent Centers for Medicare and Medicaid Services guide-
ines.
EART FAILURE SUBSETS IN WHICH
CD THERAPY IS NOT CLINICALLY INDICATED
mplantable cardioverter-defibrillator therapy should not be
sed for patients with advanced heart failure symptoms
NYHA functional class IV) that remain refractory to
ptimal medical therapy for whom cardiac transplantation is
ot an option. However, some of these patients may still be
onsidered for cardiac resynchronization therapy with ICD Mackup capability. Sweeney et al. have shown little improve-
ent in survival after ICD implantation for these patients,
ost of whom die of progressive pump failure (68). Further,
CD treatment is contraindicated in the presence of medi-
ally intractable ventricular tachycardia or ventricular fibril-
ation. Implantable cardioverter-defibrillator implantation
emains unproven for patients with substantially impaired
ystolic function and coronary artery disease, who lack
vidence of sustained or non-sustained ventricular tachycar-
ia and are scheduled to undergo coronary revascularization.
ARDIAC RESYNCHRONIZATION
HERAPY IN HEART FAILURE
vidence of ventricular dyssynchrony can be noted on the
urface ECG as prolongation of the QRS interval, most
ften with a left bundle branch block pattern. Prolongation
f the QRS complex has been associated with diminished
ardiac function, more advanced heart failure symptoms,
nd increased mortality (69–71). Approximately 30% of
atients with NYHA functional class III or IV heart failure
ymptoms will have significant QRS prolongation. Unlike
raditional right ventricular pacing, cardiac resynchroniza-
ion uses a left ventricular lead that is positioned on the
ateral wall of the left ventricle via the coronary sinus or a
ead surgically placed directly on the left ventricle epicar-
ium. This additional ventricular lead ensures stimulation of
he left ventricle at or near the time of right ventricular
epolarization. Resynchronization therapy is associated
cutely with improved contractility, decreased mitral regur-
itation, and lower left ventricular filling pressures.
Proper selection of those patients most likely to benefit
rom resynchronization therapy is imperative (Table 7). The
ublished literature suggests that only 60% to 70% of
atients currently undergoing biventricular pacing experi-
nce measurable clinical improvement from this therapy. In
ost series, biventricular pacing does not improve patients
hen left ventricular ejection fraction exceeds 40%, because
eart failure is largely due to diastolic dysfunction in this
opulation. Ambulatory patients with severe (NYHA func-
ional class III or IV) symptoms despite optimized oral
able 7. Potential Predictors of Patient Responsiveness to
ardiac Resynchronization Therapy Based on Published Studies
linical/electrocardiographic
NYHA functional class III or IV symptoms
Sinus rhythm
Wide QRS (120 ms)
easures of contractility
Ejection fraction (35%)
Basal dP/dtmax
Doppler diastolic-to-cycle length ratio
yssynchrony analysis
MRI
Tissue Doppler/strain rate analysis
Contrast echocardiography
Phase analysis ()
Septal/posterior wall motion delayRI  magnetic resonance imaging; NYHA  New York Heart Association.
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Implantable Cardioverter-Defibrillators April 18, 2006:1507–17harmacological therapy (including a flexible diuretic regi-
en, an angiotensin-converting enzyme inhibitor, and a
eta-blocker, with or without an aldosterone antagonist)
eem to derive the most benefit. Within that population,
linical trials have generally focused on patients in normal
inus rhythm who have a QRS duration 130 ms. Clinical,
lectrocardiographic, echocardiographic, and other imaging
odalities have been explored to better predict those most
ikely to benefit from resynchronization therapy. Biventricu-
ar pacing is not indicated as rescue therapy for patients with
ardiogenic shock and has not been validated for patients
ho require intermittent or continuous inotropic support or
hose supported by intra-aortic balloon counterpulsation.
uccessful biventricular pacing typically results in an im-
rovement in symptoms by one NYHA functional class and
t least 20% improvement in Minnesota Living with Heart
ailure Questionnaire scores.
Cardiac resynchronization therapy has also been shown
o enhance both submaximal and maximal exercise capacity
as assessed by 6-min walk distance and peak oxygen uptake
n cardiopulmonary exercise testing, respectively). The
ultisite Stimulation in Cardiomyopathies (MUSTIC)
rial enrolled 67 patients with NYHA functional class III
ymptoms in a single-blind, randomized, controlled cross-
ver study (72). All patients were in sinus rhythm and had
QRS duration 150 ms. Patients underwent three
onths of biventricular pacing and three months of inactive
acing (VVI backup at 40 beats/min). A significant im-
rovement in six-minute walk distance (30 m or more)
as observed only during active pacing (72).
Similarly, the Multicenter InSync Randomized Clinical
valuation (MIRACLE) trial randomized 453 patients
ith moderate to severe heart failure symptoms to biven-
ricular pacing or continued medical therapy for six months
73). Patients assigned to cardiac resynchronization expe-
ienced an improvement in their six-minute walk distance
hen compared with the control group (39 m vs. 10
) (p  0.005) (73). Cardiac resynchronization therapy
as also been shown to reduce hospitalizations for heart
ailure in the CONTAK-CD, InSync ICD (74), and
IRACLE trials (73). A meta-analysis of these three
ivotal studies showed a reduction in heart failure hos-
italizations by 29% (odds ratio, 0.71; 95% confidence
nterval, 0.53 to 0.96) (75).
The MIRACLE trial was the first to show that cardiac
esynchronization therapy could decrease the time to death
r hospitalization for worsening heart failure (73). In this
tudy, death from any cause was reduced by 27% (p  0.4).
owever, the composite end point of death or worsening
eart failure requiring hospitalization was reduced by 40%
p  0.03) (73). A recent meta-analysis reported cardiac
esynchronization therapy to be associated with a trend
oward reduced all-cause mortality (odds ratio, 0.77; 95%
onfidence interval, 0.51 to 1.18) (75). Absolute rates of
ll-cause mortality, based on pooled data over three to six ponths of follow-up, were 4.9% in the resynchronization
roup versus 6.3% in the control group.
The Comparison of Medical Therapy, Pacing and Defi-
rillators in Chronic Heart Failure (COMPANION) trial
as the first large-scale prospective trial of cardiac resyn-
hronization therapy to directly examine its effects on
ll-cause mortality (76). A total of 1,520 patients with
schemic or non-ischemic cardiomyopathy, left ventricular
jection fractions 35%, and NYHA functional class III or
V symptoms were randomized to optimal medical therapy,
iventricular pacing alone, or biventricular pacing combined
ith ICD. There was a trend toward reduction in all-cause
ortality in patients assigned to biventricular pacing (abso-
ute mortality, 14.4% for pacing alone versus 19% for
ontrol patients). However, patients who received biventricu-
ar pacing plus an ICD had a statistically significant reduction
n all-cause mortality (absolute mortality, 11%; p 0.01). The
ecently published Cardiac Resynchronization-Heart Failure
CARE-HF) study further confirmed the mortality benefit of
ardiac resynchronization therapy in 813 patients with ad-
anced symptomatic heart failure caused by left ventricular
ystolic dysfunction (77). Among patients with severe heart
ailure (NYHA functional class III or IV) and evidence of
entricular dyssynchrony, cardiac resynchronization resulted
n a significant improvement over standard pharmacological
herapy in the composite primary end point of death from
ny cause or unplanned hospitalization for a major cardio-
ascular event (p  0.001) (77). Additionally, cardiac
esynchronization therapy resulted in significant reductions
n the interventricular mechanical delay, end-systolic vol-
me index, and mitral regurgitant jet area when compared
ith medical therapy (77). Additional trials are underway to
etermine whether biventricular pacing alone will provide a
ong-term survival benefit. Thus, current practice guidelines
upport the use of biventricular pacing in patients with
dvanced (NYHA functional class III or IV) heart failure
ymptoms due to either ischemic or primary cardiomyopa-
hy when sinus rhythm, QRS prolongation (120 ms), left
entricular enlargement (left ventricular end-diastolic di-
ension 55 mm), and left ventricular systolic dysfunction
left ventricular ejection fraction 35%) exist (79).
RE-EXISTING PACER UPGRADE TO
ARDIAC RESYNCHRONIZATION THERAPY
he utility of revising standard VVI or DDD pacemakers
or patients who are pacer dependent and have chronic heart
ailure symptoms is being re-examined in light of the results
f the Dual Chamber and VVI Implantable Defibrillator
DAVID) trial (79). When patients with DDD rate-
esponsive pacing (set at 70 beats/min) were compared with
cohort with VVI pacing (set at 40 beats/min), there was a
rend toward increased mortality and hospitalizations for
ew-onset heart failure in the DDDR group (78). These
ndings suggest that unnecessary right ventricular apical
acing may induce ventricular dyssynchrony and should be
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mpaired systolic function. Similarly, an increased incidence
f heart failure was noted in the MADIT-II trial cohort
andomized to ICD therapy who showed a high frequency
f right ventricular pacing. Both studies represent retrospec-
ive post-hoc analyses and should be interpreted cautiously.
rospective controlled trials are necessary to determine
hether heart failure patients who require frequent conven-
ional pacing from a standard pacer or ICD may benefit
orm an upgrade to a biventricular model. Finally, cardiac
esynchronization therapy has been largely studied among
atients with advanced (NYHA functional class III or IV)
eart failure symptoms. Echocardiographic studies have
hown substantial reverse remodeling in this population.
hether this approach should be applied earlier to patients
ith asymptomatic left ventricular dysfunction or mild heart
ailure (NYHA functional class I or II) requires further
linical trials.
ONCLUSIONS
ver the past two decades, multiple clinical trials have
ocumented the dramatic survival benefit of ICD therapy in
ertain subsets of patients. The ICDs should be considered
rst-line therapy for survivors of life-threatening ventricular
rrhythmic events. Additionally, subsets of patients with
nherited pro-arrhythmic syndromes, such as long QT
yndrome, Brugada syndrome, hypertrophic cardiomyopa-
hy, and arrhythmogenic right ventricular dysplasia have
hown substantial survival benefits after undergoing ICD
mplantation. Recent trials have also clearly defined spe-
igure 1. Ejection fraction (EF) and implantable cardioverter-defibrillato
raction (LVEF) is a predictor of increased sudden cardiac death risk and m
ave shown that ICD therapy confers a significant survival benefit when i
f cardiac arrest, ischemic cardiomyopathy patients, and possibly dilated c
upport ICD implantation in each of these groups. *The Defibrillators in N
trend toward improved overall survival in patients with non-ischemic dil
ignificance (p  0.08). AVID  Antiarrhythmics Versus Implantable D
rrest Study Hamburg; CIDSCanadian Implantable Defibrillator Study
and II); MI  myocardial infarction; MUSTT  Multicenter Unsustain
rial.ific subsets of patients with both ischemic and dilated/on-ischemic cardiomyopathies who benefit from ICDs.
t is clear from the studies summarized in this review that
CD therapy has an increasing role in the management of a
iverse population of cardiac patients. A reduced left ven-
ricular ejection fraction predicts an increased risk for
udden cardiac death and identifies many subpopulations
hat benefit from ICD therapy. Reduced left ventricular
jection fraction as an indication for ICD implantations as
ell as the supporting clinical trials are summarized in
igure 1. Finally, cardiac resynchronization therapy has also
een shown to produce substantial symptomatic improve-
ent and survival benefits in a subgroup of chronic heart
ailure patients. This therapy should be considered in all
atients undergoing ICD implantation who have evidence
f ventricular dyssynchrony. Table 7 lists variables that may
otentially predict patients likely to have a response to
ardiac resynchronization therapy.
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ransplantation Unit, Bigelow 800, Mailstop 817, 55 Fruit Street,
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